Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
Saved in:
| Title: | Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. |
|---|---|
| Authors: | Pieri L; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Paoli C; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Arena U; Internal Medicine and Hepatology, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy., Marra F; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Mori F; Department of Cardiology, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy., Zucchini M; Department of Cardiology, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy., Colagrande S; Department of Experimental and Clinical Biomedical Sciences, University of Florence - Azienda Ospedaliera-Universitaria Careggi, Florence, Italy., Castellani A; Department of Experimental and Clinical Biomedical Sciences, University of Florence - Azienda Ospedaliera-Universitaria Careggi, Florence, Italy., Masciulli A; Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy., Rosti V; IRCCS Policlinico San Matteo Foundation, Center for the Study of Myelofibrosis, Biotechnology Research Area, Pavia, Italy., De Stefano V; Institute of Hematology, Catholic University, Rome, Italy., Betti S; Institute of Hematology, Catholic University, Rome, Italy., Finazzi G; Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy., Ferrari ML; Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy., Rumi E; Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Ruggeri M; Department of Hematology, San Bortolo Hospital, Vicenza, Italy., Nichele I; Department of Hematology, San Bortolo Hospital, Vicenza, Italy., Guglielmelli P; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Fjerza R; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Mannarelli C; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Fanelli T; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; University of Siena, Siena, Italy., Merli L; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Corbizi Fattori G; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.; University of Siena, Siena, Italy., Massa M; IRCCS Policlinico San Matteo Foundation, Biotechnology Research Area, Pavia, Italy., Cimino G; Department of Cellular Biotechnology and Hematology, University 'La Sapienza', Rome, Italy., Rambaldi A; Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy., Barosi G; IRCCS Policlinico San Matteo Foundation, Center for the Study of Myelofibrosis, Biotechnology Research Area, Pavia, Italy., Cazzola M; Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Barbui T; Hospital Papa Giovanni XXIII and Research Foundation, Bergamo, Italy., Vannucchi AM; CRIMM-Centro Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.; DenoThe Excellence Center, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. |
| Source: | American journal of hematology [Am J Hematol] 2017 Feb; Vol. 92 (2), pp. 187-195. |
| Publication Type: | Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
